看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。) L; `) S% L* f8 F) r8 V; n' o
: Y6 K& V& f- a) q# k
' x2 k3 \% ^5 t- f4 w9 yCurrently available feasibility data for possible combination strategies. 0 M' ~. C% J3 H, @% t
————————————————————————————————
+ Z; V. d% P6 UCombination Feasibility according to preliminary data
3 w* Q8 M9 L; @# q: @: t. U——————————————————————————————————
) Y% ?( V) c: y& o. K" V, _3 d1 ABevacizumab + sorafenib Yes, reduced dose / v4 w, K) T4 ~3 F$ S, C" X! k
Bevacizumab + sunitinib† No 7 A6 @; P6 x0 [9 ?* B6 S' W
Bevacizumab + temsirolimus Yes
. _1 W8 \& f1 E z$ J( T$ MBevacizumab + everolimus Yes ) z& J* i: @' p6 z# q$ q
Sorafenib + sunitinib ?
" V0 o/ S4 V' L; ?0 FSorafenib + temsirolimus Yes, reduced dose : B4 Q7 o% E4 I) W
Sorafenib + everolimus Yes, reduced dose , |4 W! F5 C! U4 \% p2 _7 ?
Sunitinib + temsirolimus† No
3 W% v+ W0 r3 h; w9 Q( [Sunitinib + everolimus ? 4 R+ X. i! j. K' A1 p* e4 o4 ]; B
Temsirolimus + everolimus ? 7 g' X! O# Q8 a& _+ I3 L3 i: A6 e
————————————————————5 v7 L2 r- Q0 p( f
†Led to US FDA warning.' V, N0 U2 j! {' j) v
?: As yet unattempted combination.
1 l2 _5 Q; z) [. X: V! K |